We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Lee Schwartzberg
Mar 14, 2022
This appears to be a case of de novo HER2+ MBC with an oligometastases to the sternum. Curative, or at least prolonged DFS is a reasonable intent here. First, I assume a thorough look for addtional metastases was performed, including possibly MRI of the skeleton as in my experience it is more sensitive even than PET scan (which should also be performed). I would irradiate the sternal lesion after TCHP, even if the tumor is clinically resolved as toxicity is small and there is some potential benefit for residual disease. If the response in the breast was excellent, I would resect the primary. Although the recent cooperative group trial was negative for survival advantage for resecting the primary in de novo MBC, I believe oligomets in HER2+ might represent a special subgroup where results could be more favorable. After treating known sites of disease, I would place the patient on maintenance HP and endocrine therapy. Would strongly consider ovarian function suppression and an AI for the endocrine component. I do not see a strong rationale for ICI in this case and would not use.
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Lee Schwartzberg
Mar 14, 2022
Apr 19, 2024
Pending Moderator approval.